ClearPoint Neuro (CLPT) Shareholder's Equity Growth (3y) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | ClearPoint Neuro | 375.84 Mn | 340.24 Mn | 7.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.69% |
| Dec 31, 2025 | -8.76% |
| Sep 30, 2025 | -26.44% |
| Jun 30, 2025 | -22.75% |
| Mar 31, 2025 | -24.11% |
| Dec 31, 2024 | -19.56% |
| Sep 30, 2024 | -13.05% |
| Jun 30, 2024 | -12.50% |
| Mar 31, 2024 | -7.70% |
| Dec 31, 2023 | 107.29% |
| Sep 30, 2023 | 444.80% |
| Jun 30, 2023 | 173.55% |
| Mar 31, 2023 | 127.72% |
| Dec 31, 2022 | 100.36% |
| Sep 30, 2022 | 87.93% |
| Jun 30, 2022 | 83.70% |
| Mar 31, 2022 | 369.23% |
| Dec 31, 2021 | 218.50% |
| Sep 30, 2021 | 160.61% |
| Jun 30, 2021 | 137.97% |
| Mar 31, 2021 | 110.00% |
| Dec 31, 2020 | -25.84% |
| Dec 31, 2019 | 100.55% |
| Sep 30, 2019 | 118.67% |
| Jun 30, 2019 | 55.25% |
| Mar 31, 2019 | 28.51% |
| Dec 31, 2018 | 40.31% |
| Sep 30, 2018 | 34.41% |
| Jun 30, 2018 | 37.60% |
| Mar 31, 2018 | 49.01% |
| Dec 31, 2017 | 291.69% |
| Dec 31, 2016 | 51.99% |
| Sep 30, 2016 | 28.11% |
| Jun 30, 2016 | -12.04% |
| Mar 31, 2016 | -24.53% |
| Dec 31, 2015 | 36.85% |
| Sep 30, 2015 | 14.82% |
| Jun 30, 2015 | 18.17% |
| Mar 31, 2015 | 34.13% |
| Dec 31, 2014 | 83.38% |